Latest Breaking News On - Ronac mamtani - Page 1 : comparemela.com

Evolving Use of PARP Inhibitors Requires Biomarker-Driven Approaches to Treatment Selection in Prostate Cancer

Vivek K. Narayan, MD, MS, spotlights 3 case studies of patients with metastatic prostate cancer, delving into the influence of their unique mutational status on treatment decisions, scenarios in which to utilize PARP inhibitor monotherapy vs combination regimens, and key trials that support the use of each approach.

Maintenance Avelumab Uptake Modest in Advanced Urothelial Carcinoma

The approval and uptake of maintenance avelumab for urothelial carcinoma is associated with upstream firstline treatment selection.

Penn Medicine, Philadelphia: First Mutation-Targeted Bladder Cancer Drug May Be Under-Used | India Education | Latest Education News | Global Educational News

UPenn Researchers Find Low Uptake of Janssen's Balversa in Eligible Bladder Cancer Patients

While low FGFR biomarker testing rates may be contributing to the drug's slow adoption, the analysis found low uptake even among patients who did get tested.

Penn study finds low uptake of first mutation-targeted bladder cancer drug

The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.